Analyses of Potential Predictive Markers and Survival Data for a Response to Sunitinib in Patients with Metastatic Renal Cell Carcinoma

BACKGROUND: Patients with metastatic clear cell renal cell carcinoma (ccRCC) are frequently treated with tyrosine kinase inhibitors (TKI) such as sunitinib. It inhibits angiogenic pathways by mainly targeting the receptors of VEGF and PDGF. In ccRCC, angiogenesis is characterized by the inactivation...

Descripción completa

Detalles Bibliográficos
Autores principales: Dornbusch, Juana, Zacharis, Aristeidis, Meinhardt, Matthias, Erdmann, Kati, Wolff, Ingmar, Froehner, Michael, Wirth, Manfred P., Zastrow, Stefan, Fuessel, Susanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3785463/
https://www.ncbi.nlm.nih.gov/pubmed/24086736
http://dx.doi.org/10.1371/journal.pone.0076386

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3785463/
https://www.ncbi.nlm.nih.gov/pubmed/24086736
http://dx.doi.org/10.1371/journal.pone.0076386

Ejemplares similares